2001 Fiscal Year Final Research Report Summary
Basic research on angiogenesis in neuroblastomas
| Project/Area Number |
12671742
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatric surgery
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
KOMURO Hiroaki Institute of Clinical Medicine, University of Tsukuba, Assistant Prof., 臨床医学系, 講師 (80296128)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KANEKO Michio Institute of Clinical Medicine, University of Tsukuba, Professor, 臨床医学系, 教授 (60152807)
|
|---|
| Project Period (FY) |
2000 – 2001
|
| Keywords | Neuroblastoma / Angiogenesis / VEGF / bFGF / PD-ECGF |
|---|
| Research Abstract |
The growth and metastasis of malignant tumors is largely dependent on angiogenesis. Angiogenic factors produced by tumor cells are known to promote tumor angiogenesis. The aim of this study is to investigate which angiogenic factor is the most important in the progression of neuroblastoma (NB). Procedure : The relative expression levels of vascular endothelial growth factor -A (VEGF-A), VEGF-C, basic fibroblast growth factor (bFGF), and platelet-derived endothelial growth factor (PD-ECGF/TP) were studied in 28 NB tumor specimens by real-time quantitative reverse transcriptase/polymerase chain reaction (RT-PCR). The relationships between the expression of these four angiogenic factors and stage, patient age, primary site, MYCN copy number, and lymph node metastasis were analyzed. Results: High VEGF-A expression was correlated with stage 4 disease (blood-borne metastasis). No relationship between VEGF-A expression and age, primary site, MYCN copy number, or lymph node metastasis was found. VEGF-C, bFGF, or PD-ECGF/TP expressions showed no correlation with stage, age, primary site, MYCN copy number, or lymph node metastasis. Conclusions : Our findings suggest that VEGF-A may be associated with progression of NB. VEGF-A could be a target for antiangiogenic therapy for disseminated NB.
|
